

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of Unaudited financial results for the quarter and six months ended 30 September 2018

SI No.	Particulars	Rs in lakhs except for earnings per share data					
		3 months ended 30/09/2018 (Unaudited)	Previous 3 months ended 30/06/2018 (Unaudited)	Corresponding 3 months ended in the previous year 30/09/2017 (Unaudited)	6 months ended 30/09/2018 (Unaudited)	6 months ended 30/09/2017 (Unaudited)	Previous year ended 31/03/2018 (Audited)
1	Revenue						
	a) Revenue from operations	16,136.08	16,143.68	16,425.83	32,279.76	29,272.41	57,198.92
	b) Other income	335.45	342.28	249.57	677.73	714.98	1,224.76
	Total revenue	16,471.53	16,485.96	16,675.40	32,957.49	29,987.39	58,423.68
2	Expenses						
	(a) Cost of materials consumed	946.41	1,687.33	312.40	2,633.74	860.17	2,788.01
	(b) Purchase of stock-in-trade	2,736.24	1,999.45	4,778.19	4,735.69	10,622.15	20,421.17
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,590.00	1,648.04	254.76	3,238.04	(1,622.43)	(5,099.57)
	(d) Excise duty	-	-	-	-	98.50	98.50
	(e) Employee benefits expense	4,495.17	4,307.28	3,640.19	8,802.45	7,134.07	15,353.09
	(f) Depreciation and amortisation expense	367.38	355.04	374.85	722.42	745.65	1,473.75
	(g) Selling, marketing and distribution expense	1,168.43	2,862.02	1,526.49	4,030.45	2,712.40	7,280.51
	(h) Other expenses	3,723.52	2,711.61	2,348.84	6,435.13	5,280.90	11,728.21
	(i) Finance cost	-	-	-	-	-	-
	Total expenses	15,027.15	15,570.77	13,235.72	30,597.92	25,831.41	54,043.67
3	Profit before exceptional and extraordinary items and tax (1-2)	1,444.38	915.19	3,439.68	2,359.57	4,155.98	4,380.01
4	Exceptional items	-	-	-	-	-	-
5	Profit before extraordinary items and tax (3+4)	1,444.38	915.19	3,439.68	2,359.57	4,155.98	4,380.01
6	Extraordinary items	-	-	-	-	-	-
7	Profit before tax (5+6)	1,444.38	915.19	3,439.68	2,359.57	4,155.98	4,380.01
8	Tax expense						
	- Current tax	437.87	263.47	698.77	701.34	851.37	899.74
	- Deferred tax	93.35	12.38	2.43	105.73	(13.60)	888.79
	Total tax expense	531.22	275.85	701.20	807.07	837.77	1,788.53
9	Profit for the period (7-8)	913.16	639.34	2,738.48	1,552.50	3,318.21	2,591.48
10	Other comprehensive income, net of income tax						
	A. Items that will not be reclassified to profit or loss	(36.62)	166.51	(9.43)	129.89	52.93	(227.99)
	B. Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income, net of income tax	(36.62)	166.51	(9.43)	129.89	52.93	(227.99)
	Total comprehensive income for the period (9+10)	876.54	805.85	2,729.05	1,682.39	3,371.14	2,363.49
11	Earnings per equity share of Rs 2/- each (basic and diluted)	3.65	2.56	10.95	6.21	13.27	10.37




Jagan

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of Unaudited financial results for the quarter and six months ended 30 September 2018

Notes:

- 1 The Statutory Auditors have carried out a Limited Review of the financial results for the quarter and six months ended 30 September 2018 including Balance sheet as at 30 September 2018 (the 'statement') as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statement has been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 13 November 2018.
- 2 The Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 Ind AS 115 'Revenue from contracts with customers' mandatory for reporting periods beginning on or after 1 April 2018, replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 1 April 2018. The adoption of the standard did not have any impact on the financial results for the quarter and for the six months ended 30 September 2018.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 As previously disclosed, by way a of letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 6 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.

**By Order of the Board of Directors
For AstraZeneca Pharma India Limited**


**Gagandeep Singh Bedi
Managing Director**

**Place: New Delhi
Date: 13 November 2018**



AstraZeneca Pharma India Limited
Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Unaudited Statement of assets and liabilities as at 30 September 2018

(Rs in lakhs)

SI.No.	Balance Sheet	As at 30 September 2018 (Unaudited)	As at 31 March 2018 (Audited)
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	7,320.23	7,546.02
	(b) Capital work-in-progress	712.58	357.27
	(c) Financial Assets		
	(i) Investments	-	-
	(ii) Loans	280.78	263.85
	(iii) Current tax assets	1,796.75	2,356.04
	(iv) Deferred tax assets	2,934.72	3,255.29
	(d) Other non-current assets	102.23	184.10
	Sub-total - Non-current assets	13,147.29	13,962.57
2	Current assets		
	(a) Inventories	7,886.47	11,315.10
	(b) Financial Assets		
	(i) Trade receivables	6,007.91	5,462.54
	(ii) Cash and cash equivalents	18,744.38	11,398.24
	(iii) Bank balances other than (ii) above	5.75	1,194.00
	(iv) Loans	95.69	123.94
	(v) Other financial current assets	1,017.76	353.71
	(c) Other current assets	1,816.32	2,243.82
	Sub-total - Current assets	35,574.28	32,091.35
	TOTAL - ASSETS	48,721.57	46,053.92
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	500.00	500.00
	(b) Other Equity	25,846.13	24,193.18
	Sub-total - Shareholders' funds	26,346.13	24,693.18
	LIABILITIES		
	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Other financial liabilities	-	-
	(b) Other non-current liabilities	-	-
	(c) Provisions	208.99	665.77
	Sub-total - Non-current liabilities	208.99	665.77
2	Current liabilities		
	(a) Financial Liabilities		
	(i) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	9.04	2.00
	Total outstanding dues of creditors other than micro enterprises and small enterprises	14,971.49	12,717.87
	(ii) Other financial liabilities	2,936.34	3,185.11
	(b) Other current liabilities	622.16	756.36
	(c) Provisions	3,092.08	3,498.12
	(d) Current tax liability	535.34	535.51
	Sub-total - Current liabilities	22,166.45	20,694.97
	TOTAL - EQUITY AND LIABILITIES	48,721.57	46,053.92



Jagan